

Gynaecomastia

Definition / Supporting Information

Gynaecomastia is enlargement of the male breast tissue, defined as the presence of > 2 cm of palpable, firm, subareolar gland and ductal breast tissue. Gynaecomastia occurs during early puberty in up to 75% of males. The large majority of these do not require investigation but can be reassured.

Essential History

Ask about:

- Onset and duration of breast enlargement
- Tenderness
- Growth
- Developmental milestones
- Significant illnesses
 - Malnutrition
- Medications
 - Diethylstilbestrol
 - Digoxin
 - Domperidone
 - Chorionic gonadotrophin
 - Spironolactone
 - Isoniazid
 - Methyldopa
 - Captopril
 - Tricyclic antidepressants
 - Diazepam
 - Phenothiazines
 - Risperidone

'Red Flag' Symptoms and Signs

Ask about:

- Delayed developmental milestones
- Dyspraxia and co-ordination problems
- Attention problems

- Mild learning disabilities
- Dyslexia or reading problems
- Behavioural problems

Look for:

- Abnormal growth parameters and / or velocity (see [Faltering Growth](#))
- Signs of late puberty (See [Tanner Stage G4](#), [Child Growth Foundation \(pdf\)](#))
 - Gynaecomastia is a common and normal observation in early puberty (G2–3) but usually resolves by late puberty (G4)
- Small testes
- Decreased or absent facial or sexual hair

Differential Diagnosis / Conditions

- Normal feature of early male puberty
- Pseudogynaecomastia due to increased adiposity
- Klinefelter's syndrome
- Partial androgen insensitivity syndrome
- Hyperprolactinaemia
- Liver disorders
- Adrenal carcinoma
- Biosynthetic defects in testosterone production
- Increased activity of peripheral aromatase (feature of obesity)
- Medication effect:
 - Oestrogen-like effect
 - Diethylstilbestrol
 - Digoxin
 - Increase in oestrogen formation
 - Chorionic gonadotrophin
 - Inhibition of testosterone action
 - Spironolactone
 - Methyldopa
 - Phenothiazines
 - Risperidone

Investigations

To be undertaken by non-specialist practitioners (eg, General Practitioner (GP) Team) or by specialist practitioners (eg, General Paediatric / Paediatric Endocrinology Team(s)):

- None initially unless 'red flag' symptoms or signs are present, in which case:
 - Urea and electrolytes

- Blood glucose
- Consider thyroid function
- Liver function tests
- Testosterone
- Oestradiol
- Luteinising hormone
- Follicle-stimulating hormone
- Liver function tests
- Prolactin
- β -Human chorionic gonadotrophin
- Ultrasonography of breast tissue
 - If breast tissue feels abnormal

Treatment Approach

To be undertaken by non-specialist practitioners (eg, GP Team) or by specialist practitioners (eg, General Paediatric / Paediatric Endocrinology Team(s)):

- All that is required in most cases is reassurance that gynaecomastia is normal and self-limiting in the majority of cases.

To be undertaken by specialist practitioners (eg, General Paediatric / Paediatric Endocrinology Team(s)):

- For unresolved or rapidly developing cases:
 - Medical therapy
 - Tamoxifen (oestrogen antagonist)
 - Danazol (gonadotrophin modulator)
 - **No randomised controlled trials have assessed these drugs in children.**
 - Surgical intervention if failure to respond to removal of cause or medical treatment
 - Breast reduction surgery is not usually available in the NHS; individual funding would need to be sought.

When to Refer

Refer to specialist practitioners (eg, General Paediatric / Paediatric Endocrinology Team(s)) if:

- 'Red flag' signs or symptoms are present
- Gynaecomastia does not resolve after 2 years
- Gynaecomastia develops rapidly

‘Safety Netting’ Advice

Advise patient to consult GP if the breast(s) grow(s) larger or become(s) painful, or if there are any new symptoms.

Patient / Carer Information

****Please note: whilst these resources have been developed to a high standard they may not be specific to children.***

- [What is gynaecomastia?](#) (Web page), the NHs website
- [Gynaecomastia](#) (Information leaflet), Breast Cancer Care

Resources

Suggested Resources

****Please note: these resources include links to external websites. These resources may not have national accreditation and therefore PCO UK cannot guarantee the accuracy of the content.***

Tanner, JM. Growth and endocrinology of the adolescent. In: Gardner, LI, ed. *Endocrine and Genetic Diseases of Childhood and Adolescence*. Philadelphia, PA: WB Saunders; 1975.

Acknowledgements

Content Editor: Dr Jan Dudley

Clinical Expert Reviewers: Dr John Barton

GP Reviewer: Dr Ian A Dunn

AAP Reviewer: Jane Meschan Foy, MD, FAAP

Paediatric Trainee Reviewer: Dr Emma Parish

Paediatric Specialty Group: [British Society for Paediatric Endocrinology and Diabetes](#)

Update information

Created: 2015

Date last updated: -

Next review due: 2018